The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget’s disease of bone
- 1 May 2001
- Vol. 28 (5), 461-464
- https://doi.org/10.1016/s8756-3282(01)00431-8
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseasesArthritis & Rheumatism, 2000
- Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL-6 and MMP-1 by the Tumoral EnvironmentJournal of Bone and Mineral Research, 1999
- Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronateMatrix Biology, 1999
- Measurement of urinary excretion of nonisomerized and ?-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's diseaseArthritis & Rheumatism, 1998
- Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate).Calcified Tissue International, 1997
- Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three‐year randomized, double‐blind trialArthritis & Rheumatism, 1996
- Biochemical Characterization of Human Collagenase-3Journal of Biological Chemistry, 1996
- Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatmentJournal of Clinical Endocrinology & Metabolism, 1994
- Effect of clodronate on established adjuvant arthritisRheumatology International, 1994
- Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritisArthritis & Rheumatism, 1979